Phoenix NP announced a continued rise in patient satisfaction across Arizona, noting that positive feedback has increased as more women seek safe, FDA-approved GLP-1 weight loss medications through ...

Weight loss drug Ozempic was launched in India on Friday, with 0.25mg doses priced at $24.35 a week. Pharmaceutical company ...

A weight loss drug dubbed the "triple G" drug for its effectiveness in mimicking three hunger-regulating hormones showed promising results in new data released Thursday by its maker, Eli Lilly.

Kantar's research shows 31 per cent of Canadians surveyed said their taste in food had changed since being on the drug. In the U.S., notable numbers of GLP-1 patients are skipping processed food or ...

This article highlights the impact of diabetes on the community, with 13% of adults in Florence County living with the ...

The maker of the blockbuster weight loss and diabetes drugs Wegovy and Ozempic have cut the prices for most versions of these medications. Novo Nordisk dropped the price for injectable Wegovy and ...

Novo Nordisk is chopping prices again for Wegovy, but doctors say the expense will remain challenging for patients without insurance. The drugmaker said Monday that it has started selling higher doses ...

Novo Nordisk (NVO) has cut the price of its weight-loss injection Wegovy by as much as 37% from its launch price in India, as the Danish drugmaker plays catch-up with rival Eli Lilly (LLY), whose ...

Novo Nordisk’s oral semaglutide 25 mg achieved up to 16.6% weight loss in a landmark study, rivaling injectable Wegovy. The pill also improved cardiovascular risk factors and physical activity levels.

Hims & Hers Health (HIMS) traded ~6% higher on Tuesday after the telehealth platform, with its Q3 2025 results, said it is in "active discussions" with Novo Nordisk (NVO) to sell the Danish ...

The long-term side effects of Wegovy® may include problems with your pancreas, kidneys, or gallbladder. These side effects are rare. For many, Wegovy® is safe to use long-term, and the benefits ...

An analysis found that a shrinking waist size was responsible for only around a third of the cardiovascular benefits in people who took Wegovy. By Dani Blum A new analysis of a major clinical trial ...